专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003054228A2 HUMAN CELLULAR PROTEIN KINASES, METALLOPROTEASES AND PHOSPHATASES AS TARGETS FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译：人类细胞蛋白激酶，金属蛋白酶和磷酸盐作为对抗HEPATITIS C病毒感染的医疗干预的目标
公开(公告)号：WO2003054228A2
公开(公告)日：2003-07-03
申请号：PCT/EP2002/014578
申请日：2002-12-19
申请人： AXXIMA PHARMACEUTICALS AG , SALASSIDIS, Konstadinos , SCHUBART, Daniel , GUTBROD, Heidrun , MUELLER, Stefan , KRAETZER, Friedrich , OBERT, Sabine
发明人： SALASSIDIS, Konstadinos , SCHUBART, Daniel , GUTBROD, Heidrun , MUELLER, Stefan , KRAETZER, Friedrich , OBERT, Sabine
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6897 , C12Q1/6883 , C12Q1/707 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to human cellular protein kinases, metalloproteases and one phosphatase: beta-adrenergic receptor kinase 1 (NM_001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM_013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM_007026), ADAM22 (NM_016351), and ADAM17 (U92649) as potential targets for medical intervention against Hepatitis C virus (HCV) infections. The present invention relates also to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections, a method for detecting Hepatitis C virus infections in an individual or in cells. Mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production and/or replication wherein said antibodies may be used. Finally the present invention relates to a solid support useful for detecting Hepatitis C virus infections or for screening compounds useful for prophylaxis and/or treatment of HCV infections.
摘要翻译：本发明涉及人细胞蛋白激酶，金属蛋白酶和一种磷酸酶：β-肾上腺素能受体激酶1（NM_001619），丝裂原活化蛋白激酶活化蛋白激酶5（AF032437），胰岛素刺激蛋白激酶1（U08316），盘丝蛋白结构域受体家族成员1（NM_013994），蛋白激酶C，mu（X75756），蛋白激酶C，theta（L01087），AMP激活蛋白激酶β2亚基（AJ224538），JNK2（U09759），人p21活化蛋白激酶 2（U24153），细胞周期蛋白依赖性激酶4（U37022），MEK5（U25265），MKP-L（NM_007026），ADAM22（NM_016351）和ADAM17（U92649）作为针对丙型肝炎病毒（HCV）感染的医疗干预的潜在目标。本发明还涉及用于检测可用于预防和/或治疗丙型肝炎病毒感染的化合物的方法，用于检测个体或细胞中丙型肝炎病毒感染的方法。公开了单抗或多克隆抗体与治疗丙型肝炎病毒感染的方法以及用于调控丙型肝炎病毒生产和/或复制的方法有效用于治疗HCV感染，其中可以使用所述抗体。最后，本发明涉及用于检测丙型肝炎病毒感染或筛选用于预防和/或治疗HCV感染的化合物的固体支持物。

2. 发明申请

WO2002094796A2 BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES 审中-公开
标题翻译：苯并[G]喹啉衍生物作为有效的化合物对抗感染性疾病
公开(公告)号：WO2002094796A2
公开(公告)日：2002-11-28
申请号：PCT/EP2002/005573
申请日：2002-05-21
申请人： AXXIMA PHARMACEUTICALS AG , PATÓ, János , KÉRI, György , ÖRFI, László , WÁCZEK, Frigyes , HORVÁTH, Zoltán , BÁNHEGYI, Péter , SZABADKAI, István , MAROSFALVI, Jenö , HEGYMEGI-BARAKONYI, Bálint , SZÉKELYHIDI, Zsolt , GREFF, Zoltán , CHOIDAS, Axel , BACHER, Gerald , DAUB, Henrik , OBERT, Sabine , KURTENBACH, Alexander , HABENBERGER, Peter
发明人： PATÓ, János , KÉRI, György , ÖRFI, László , WÁCZEK, Frigyes , HORVÁTH, Zoltán , BÁNHEGYI, Péter , SZABADKAI, István , MAROSFALVI, Jenö , HEGYMEGI-BARAKONYI, Bálint , SZÉKELYHIDI, Zsolt , GREFF, Zoltán , CHOIDAS, Axel , BACHER, Gerald , DAUB, Henrik , OBERT, Sabine , KURTENBACH, Alexander , HABENBERGER, Peter
IPC分类号： C07D241/00
CPC分类号： C07D241/38 , C07D231/12 , C07D233/56 , C07D241/52 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D513/14
摘要： The present invention relates to benzo[g]quinoxaline derivatives of the general formula (I), processes for manufacturing said benzo[g]quinoxaline derivatives, the use of the benzo[g]quinoxaline derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases and opportunistic infections, diabetes, cancer, inflammation, as well as compositions containing at least one benzo[g]quinoxaline derivative and/or pharmaceutically acceptable salt thereof. Further, the present invention is directed to methods for preventing and/or treating of infectious diseases, diabetes, cancer, and inflammation using the inventive benzo[g]quinoxaline derivatives.
摘要翻译：本发明涉及通式（I）的苯并[g]喹喔啉衍生物，制备所述苯并[g]喹喔啉衍生物的方法，使用苯并[g]喹喔啉衍生物作为药物活性剂，特别是用于预防和 /或治疗感染性疾病和机会性感染，糖尿病，癌症，炎症，以及含有至少一种苯并[g]喹喔啉衍生物和/或其药学上可接受的盐的组合物。此外，本发明涉及使用本发明的苯并[g]喹喔啉衍生物预防和/或治疗感染性疾病，糖尿病，癌症和炎症的方法。

3. 发明申请

WO2002084294A3 GASTROINTESTINAL GLUTATHIONE PEROXIDASE IN HEPATITIS C VIRUS INFECTIONS 审中-公开
公开(公告)号：WO2002084294A3
公开(公告)日：2002-10-24
申请号：PCT/EP2002/004167
申请日：2002-04-15
申请人： AXXIMA PHARMACEUTICALS AG , HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
发明人： HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
IPC分类号： G01N33/576
摘要： The present invention relates to the human cellular protein glutathione peroxidase-gastrointestinal as potential targets for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections and a method for detecting Hepatitic C virus infections in an individual or in cells. Also mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production wherein said antibodies may be used.

4. 发明申请

WO0121160A3 CARBOXYMIDE AND ANILINE DERIVATIVES AS SELECTIVE INHIBITORS OF PATHOGENS 审中-公开
标题翻译：羧基和苯胺衍生物作为病原体选择性抑制剂
公开(公告)号：WO0121160A3
公开(公告)日：2002-01-31
申请号：PCT/EP0009306
申请日：2000-09-22
申请人： AXXIMA PHARMACEUTICALS AG , ULLRICH AXEL , MARSCHALL MANFRED , STAMMINGER THOMAS , WALLASCH CHRISTIAN , OBERT SABINE
发明人： ULLRICH AXEL , MARSCHALL MANFRED , STAMMINGER THOMAS , WALLASCH CHRISTIAN , OBERT SABINE
IPC分类号： A61K31/167 , A61K31/17 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/4184 , A61K31/4245 , A61K31/428 , A61K31/47 , A61K31/505 , C07C233/66 , C07C233/80 , C07C255/58 , C07C275/40 , C07D215/40 , C07D215/48 , C07D231/40 , C07D235/30 , C07D239/48 , C07D271/12 , C07D307/68 , C07D333/24 , C07D333/38 , C07D333/66 , C07D409/12 , C07D417/12 , C07D495/04 , A61P31/12 , A61P31/14
CPC分类号： C07D239/48 , A61K31/167 , A61K31/17 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/4184 , A61K31/4245 , A61K31/428 , A61K31/47 , A61K31/505 , C07C233/66 , C07C233/80 , C07C255/58 , C07C275/40 , C07D215/40 , C07D215/48 , C07D231/40 , C07D235/30 , C07D271/12 , C07D307/68 , C07D333/24 , C07D333/38 , C07D333/66 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The present invention relates to the use of carboxamide compounds as selective inhibitors of pathogens, particularly viruses and, more particularly, herpesviridae. Surprisingly, these compounds show reduced side effects in comparison with previous antiviral compounds. Thus, a novel method for preventing or treating infections by pathogens, particularly herpesviridae is provided.
摘要翻译：本发明涉及甲酰胺化合物作为病原体的选择性抑制剂的用途，特别是病毒，更特别是疱疹病毒科。令人惊讶的是，与先前的抗病毒化合物相比，这些化合物显示出减少的副作用。因此，提供了一种预防或治疗病原体特别是疱疹病毒科感染的新方法。

5. 发明申请

WO2002084294A2 HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译：人类细胞蛋白GASTROINTESTINAL GLUTATHIONE过氧化物作为针对乙型肝炎病毒感染的医疗干预措施
公开(公告)号：WO2002084294A2
公开(公告)日：2002-10-24
申请号：PCT/EP2002/004167
申请日：2002-04-15
申请人： AXXIMA PHARMACEUTICALS AG , HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
发明人： HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
IPC分类号： G01N33/576
CPC分类号： C12N9/0065 , A61K31/00 , A61K38/00 , A61K48/00 , A61K2039/505 , C12N2501/24 , C12Q1/28 , C12Y111/01009 , G01N33/573 , G01N33/5767 , G01N2333/18 , G01N2333/908 , G01N2500/04
摘要： The present invention relates to the human cellular protein glutathione peroxidase-gastrointestinal as potential targets for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections and a method for detecting Hepatitic C virus infections in an individual or in cells. Also mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production wherein said antibodies may be used.
摘要翻译：本发明涉及人类细胞蛋白谷胱甘肽过氧化物酶 - 胃肠道作为针对丙型肝炎病毒（HCV）感染的医疗干预的潜在靶标。此外，本发明涉及用于检测可用于预防和/或治疗丙型肝炎病毒感染的化合物的方法和用于检测个体或细胞中的肝炎C病毒感染的方法。还公开了对治疗HCV感染有效的单克隆抗体或多克隆抗体以及用于治疗丙型肝炎病毒感染的方法或用于调控可以使用所述抗体的丙型肝炎病毒生产。

6. 发明申请

WO0121160B1 CARBOXYMIDE AND ANILINE DERIVATIVES AS SELECTIVE INHIBITORS OF PATHOGENS 审中-公开
标题翻译：作为病原体的选择性抑制剂的羧甲氧基化物和苯胺衍生物
公开(公告)号：WO0121160B1
公开(公告)日：2002-05-30
申请号：PCT/EP0009306
申请日：2000-09-22
申请人： AXXIMA PHARMACEUTICALS AG , ULLRICH AXEL , MARSCHALL MANFRED , STAMMINGER THOMAS , WALLASCH CHRISTIAN , OBERT SABINE
发明人： ULLRICH AXEL , MARSCHALL MANFRED , STAMMINGER THOMAS , WALLASCH CHRISTIAN , OBERT SABINE
IPC分类号： A61K31/167 , A61K31/17 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/4184 , A61K31/4245 , A61K31/428 , A61K31/47 , A61K31/505 , C07C233/66 , C07C233/80 , C07C255/58 , C07C275/40 , C07D215/40 , C07D215/48 , C07D231/40 , C07D235/30 , C07D239/48 , C07D271/12 , C07D307/68 , C07D333/24 , C07D333/38 , C07D333/66 , C07D409/12 , C07D417/12 , C07D495/04 , A61P31/12 , A61P31/14
CPC分类号： C07D239/48 , A61K31/167 , A61K31/17 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4155 , A61K31/4184 , A61K31/4245 , A61K31/428 , A61K31/47 , A61K31/505 , C07C233/66 , C07C233/80 , C07C255/58 , C07C275/40 , C07D215/40 , C07D215/48 , C07D231/40 , C07D235/30 , C07D271/12 , C07D307/68 , C07D333/24 , C07D333/38 , C07D333/66 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The present invention relates to the use of carboxamide compounds as selective inhibitors of pathogens, particularly viruses and, more particularly, herpesviridae. Surprisingly, these compounds show reduced side effects in comparison with previous antiviral compounds. Thus, a novel method for preventing or treating infections by pathogens, particularly herpesviridae is provided.
摘要翻译：本发明涉及羧酰胺化合物作为病原体，特别是病毒，更特别是疱疹病毒科的选择性抑制剂的用途。令人吃惊的是，与以前的抗病毒化合物相比，这些化合物显示出减少的副作用。因此，提供了预防或治疗病原体，特别是疱疹病毒科感染的新方法。

7. 发明申请

WO2004005264A3 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译：咪唑类化合物治疗丙型肝炎病毒感染
公开(公告)号：WO2004005264A3
公开(公告)日：2004-03-04
申请号：PCT/EP0307286
申请日：2003-07-07
申请人： AXXIMA PHARMACEUTICALS AG , SALASSIDIS KONSTADINOS , KURTENBACH ALEXANDER , DAUB HENRIK , OBERT SABINE , GREFF ZOLTAN , KERI GYOERGY , OERFI LASZLO , WACZEK FRIGYES
发明人： SALASSIDIS KONSTADINOS , KURTENBACH ALEXANDER , DAUB HENRIK , OBERT SABINE , GREFF ZOLTAN , KERI GYOERGY , OERFI LASZLO , WACZEK FRIGYES
IPC分类号： A61K31/4178 , A61P31/20 , C07D233/54 , C07D233/64 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14
CPC分类号： C07D233/64 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14
摘要： The present invention describes novel imidazole compounds, which are particularly useful against Hepatitis C Virus infections and diseases associated therewith. Furthermore, the invention relates to the human cellular proteins casein kinase I alpha (alpha), delta (delta), and epsilon (ϵ) as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases. In addition, the present invention refers to a method for the identification of compounds which are useful for the prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical compositions useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, disclosed are antibodies, oligonucleotides and specific compounds which are effective for the detection, prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus. In addition, the present invention describes solid supports useful for the identification of compounds suitable for preventing and/or treating infections and diseases caused by said Hepatitis C Virus.
摘要翻译：本发明描述了新的咪唑化合物，其特别可用于抗丙型肝炎病毒感染和与之相关的疾病。此外，本发明涉及作为针对丙型肝炎病毒（HCV）感染和疾病的医学干预的靶标的人细胞蛋白质酪蛋白激酶Iα（α），δ（δ）和ε（ε）。此外，本发明涉及鉴定可用于预防和/或治疗由丙型肝炎病毒引起的感染和疾病的化合物的方法，治疗丙型肝炎病毒感染和疾病的方法，以及药物组合物用于预防和/或治疗丙型肝炎病毒感染和疾病。此外，公开了对检测，预防和/或治疗由丙型肝炎病毒引起的感染和疾病有效的抗体，寡核苷酸和特定化合物。此外，本发明描述了用于鉴定适合于预防和/或治疗由所述丙型肝炎病毒引起的感染和疾病的化合物的固体支持物。

8. 发明申请

WO2002094796A3 BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES 审中-公开
公开(公告)号：WO2002094796A3
公开(公告)日：2002-11-28
申请号：PCT/EP2002/005573
申请日：2002-05-21
申请人： AXXIMA PHARMACEUTICALS AG , PATÓ, János , KÉRI, György , ÖRFI, László , WÁCZEK, Frigyes , HORVÁTH, Zoltán , BÁNHEGYI, Péter , SZABADKAI, István , MAROSFALVI, Jenö , HEGYMEGI-BARAKONYI, Bálint , SZÉKELYHIDI, Zsolt , GREFF, Zoltán , CHOIDAS, Axel , BACHER, Gerald , DAUB, Henrik , OBERT, Sabine , KURTENBACH, Alexander , HABENBERGER, Peter
发明人： PATÓ, János , KÉRI, György , ÖRFI, László , WÁCZEK, Frigyes , HORVÁTH, Zoltán , BÁNHEGYI, Péter , SZABADKAI, István , MAROSFALVI, Jenö , HEGYMEGI-BARAKONYI, Bálint , SZÉKELYHIDI, Zsolt , GREFF, Zoltán , CHOIDAS, Axel , BACHER, Gerald , DAUB, Henrik , OBERT, Sabine , KURTENBACH, Alexander , HABENBERGER, Peter
IPC分类号： C07D241/38
摘要： The present invention relates to benzo[g]quinoxaline derivatives of the general formula (I), processes for manufacturing said benzo[g]quinoxaline derivatives, the use of the benzo[g]quinoxaline derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases and opportunistic infections, diabetes, cancer, inflammation, as well as compositions containing at least one benzo[g]quinoxaline derivative and/or pharmaceutically acceptable salt thereof. Further, the present invention is directed to methods for preventing and/or treating of infectious diseases, diabetes, cancer, and inflammation using the inventive benzo[g]quinoxaline derivatives.

9. 发明申请

WO0200613A3 INHIBITORS OF HEPATITIS B VIRUS INFECTION 审中-公开
标题翻译：乙型肝炎病毒感染的抑制剂
公开(公告)号：WO0200613A3
公开(公告)日：2002-11-07
申请号：PCT/EP0107260
申请日：2001-06-26
申请人： AXXIMA PHARMACEUTICALS AG , BEVEC DORIAN , OBERT SABINE
发明人： BEVEC DORIAN , OBERT SABINE
IPC分类号： A61P31/16 , C07C281/18 , A61K31/155
CPC分类号： C07C281/18
摘要： The present invention relates to inhibitors of Hepatitis B Virus (HBV). A class of guanyl hydrazones are disclosed to be powerful inhibitors of HBV infection. Such compounds are useful for the treatment of HBV infection, in particular chronic HBV infection and for the treatment of opportunistic infections and diseases caused by HBV infections. Furthermore, the present invention discloses pharmaceutical compositions useful for prophylaxis and/or treatment of HBV infections, including opportunistic infections, and diseases caused by HBV infections.
摘要翻译：本发明涉及乙型肝炎病毒（HBV）的抑制剂。公开了一类脒基腙作为HBV感染的强力抑制剂。这些化合物可用于治疗HBV感染，特别是慢性HBV感染和用于治疗由HBV感染引起的机会性感染和疾病。此外，本发明公开了可用于预防和/或治疗HBV感染，包括机会性感染和由HBV感染引起的疾病的药物组合物。

10. 发明申请

WO0156553A3 PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES 审中-公开
标题翻译：药用活性芳香GUANYLHYDRAZONES
公开(公告)号：WO0156553A3
公开(公告)日：2002-03-28
申请号：PCT/EP0101126
申请日：2001-02-02
申请人： AXXIMA PHARMACEUTICALS AG , BEVEC DORIAN , HAUBER JOACHIM , OBERT SABINE , KERI GYORGY , ORFI LASZLO , SZEKELY ISTVAN , CHOIDAS AXEL , BACHER GERALD
发明人： BEVEC DORIAN , HAUBER JOACHIM , OBERT SABINE , KERI GYORGY , ORFI LASZLO , SZEKELY ISTVAN , CHOIDAS AXEL , BACHER GERALD
IPC分类号： A61K31/155 , A61K31/17 , A61K31/22 , A61K31/4164 , A61K45/06 , A61P31/04 , A61P31/18 , C07C281/18
CPC分类号： A61K45/06 , A61K31/155 , A61K31/17 , A61K31/4164 , C07C281/18
摘要： The present invention relates to aromatic guanylhydrazone compounds and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The inventive guanylhydrazone compounds are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF- alpha production. Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram positive and Gram negative bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed together with pharmaceutical compositions useful within said methods containing at least one aromatic guanylhydrazone of the present invention as active ingredient.
摘要翻译：本发明涉及芳香脒腙化合物及其作为药物活性剂的用途，特别是用于预防和治疗病毒引起的疾病和感染，包括机会性感染。本发明的脒腙化合物也可用作脱氧酪氨酸合成酶的抑制剂，并且可用作感染性疾病中核出口的抑制剂，并可用于调节细菌诱导的TNF-α产生。此外，芳香脒腙对革兰氏阳性和革兰氏阴性细菌具有抗菌活性，可被认为是一类新型抗生素。此外，还公开了用于预防和治疗病毒或细菌诱导的感染和疾病的方法以及在含有本发明的至少一种芳香脒腙作为活性成分的所述方法中有用的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式